NCT03608371: A trial that was reported late by BlackThorn Therapeutics, Inc.
This trial has reported, although it was 1126 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03608371 |
|---|---|
| Title | Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 31, 2018 |
| Completion date | April 16, 2019 |
| Required reporting date | April 16, 2022, midnight |
| Actual reporting date | May 16, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 1126 |